Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-07-13 16:27:43 ET · period of report 2026-07-10 · accession 0001965808-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-13 16:27 | 2026-07-10 | NBIX | Delaet Ingrid | Chief Regulatory Off | M - OptEx | $106.02 | +4,367 | 20.6K | +27% | +$463.0K |
| DT | 2026-07-13 16:27 | 2026-07-10 | NBIX | Delaet Ingrid | Chief Regulatory Off | S - Sale+OE | $181.02 | -4,367 | 16.2K | -21% | -$790.5K |
| DT | 2026-07-13 16:27 | 2026-07-10 | NBIX | Delaet Ingrid | Chief Regulatory Off | M - OptEx | $0.00 | -4,367 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-10 | M | A | 4,367 | $106.02 | 20,592 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-10 | S | D | 4,367 | $181.02 | 16,225 | D | — | — | (F1) The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. |
| 3 | Derivative | Non-Qualified Stock Option | 2026-07-10 | M | D | 4,367 | $0.00 | 0 | D | $106.02 · — to 2031-02-01 | 4,367 Common Stock | (F2) Option granted February 1, 2021 and vested at 25% upon first anniversary (February 1, 2022) and remaining 75% vested in 36 equal monthly installments beginning on March 1, 2022. |